MaxCyte

MaxCyte EBITDA

The EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of MaxCyte (MXCT) as of Oct 20, 2026 is -45.29 M USD. In the previous year, EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) was -47.05 M USD — a change of -3.76% (higher).

EBITDA

-45.29 MUSD

YoY

-3.76%

Last updated:

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of MaxCyte is 2025 -45.29 M USD. EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of MaxCyte was 2024 -47.05 M USD. It decreases by -3.76% higher compared to the previous year.

The MaxCyte EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA
Date
EBITDA
Jan 1, 2018
-8.42 M USD
Jan 1, 2019
-12.42 M USD
Jan 1, 2020
-11.06 M USD
Jan 1, 2021
-16.84 M USD
Jan 1, 2022
-24.83 M USD
Jan 1, 2023
-44.31 M USD
Jan 1, 2024
-47.05 M USD
Jan 1, 2025
-45.29 M USD
The MaxCyte EBITDA history
YEAREBITDAYoY
-45.29 MUSD-3.76%
-47.05 MUSD+6.18%
-44.31 MUSD+78.46%
-24.83 MUSD+47.46%
-16.84 MUSD+52.29%
-11.06 MUSD-10.98%
-12.42 MUSD+47.42%
-8.42 MUSD-9.33%
-9.29 MUSD+241.18%
-2.72 MUSD+257.82%
-761,100.00USD-40.34%
-1.28 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

MaxCyte Stock analysis

What does MaxCyte do? MaxCyte Inc is a US biotechnology company specializing in the development of platform-based technologies for the next generation of gene and cell therapies. They offer integrated platform technology for drug manufacturing, research, and development. Their proprietary platform technology, Flow ElectroporationTM, allows for efficient transduction of a variety of cells, making it a valuable tool for the production of CAR-T cell therapies. They also offer services for lentiviral production and customized gene therapy production. MaxCyte has secured $50 million in funding for expansion and has formed important partnerships in the industry. They are a leading player in the development of innovative technologies for gene and cell therapy products. MaxCyte is one of the most popular companies on Eulerpool.

Frequently Asked Questions about MaxCyte stock

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of MaxCyte is -45.29 M USD in 2025.

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of MaxCyte changed from -47.05 M USD to -45.29 M USD, representing a -3.76% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) MaxCyte since 2006 – with annual values, charts, and detailed analysis.

EBITDA measures operating performance before the impact of financial structure, tax environment, and non-cash depreciation charges.

EBITDA = EBIT + Depreciation & Amortization

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s MaxCyte historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Income Statement — MaxCyte

RevenueGross ProfitEBITEBITDANet IncomeEPSCost of Goods SoldR&D ExpensesSG&A ExpensesOperating ExpensesInterest ExpensePretax IncomeTax ExpenseDepreciation & AmortizationRevenue per ShareEBIT per ShareDiluted EPSEBITDA per ShareOther Income/Expense

All Key Metrics — MaxCyte